Uehara et al. showed that both SG and Roux-en-Y gastric bypass (RYGB) promote a reduction of NAFLD due to the consequent weight loss and the metabolic aspects proper to the procedure, especially the action of incretins such as glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2).20 Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.